Advanced search
Publication Cover
Expert Review of Obstetrics & Gynecology Volume 7, 2012 - Issue 6
Journal homepage
9
Views
3
CrossRef citations to date
0
Altmetric
Review

The role of local vaginal estrogen treatment in urogenital atrophy

Lian Ulrich Department of Obstetrics and Gynecology, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9 2100 Copenhagen Ø, Denmark. [email protected]
Pages 545-556 | Published online: 10 Jan 2014

References

  • Huang AJ, Moore EE, Boyko EJ et al. Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors. Menopause 17(1), 121–126 (2010).
  • Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative. Maturitas 49(4), 292–303 (2004).
  • Stenberg A, Heimer G, Ulmsten U, Cnattingius S. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 24(1–2), 31–36 (1996).
  • Barlow DH, Cardozo LD, Francis RM et al. Urogenital ageing and its effect on sexual health in older British women. Br. J. Obstet. Gynaecol. 104(1), 87–91 (1997).
  • Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13(6), 509–522 (2010).
  • Versi E, Harvey MA, Cardozo L, Brincat M, Studd JW. Urogenital prolapse and atrophy at menopause: a prevalence study. Int. Urogynecol. J. Pelvic Floor Dysfunct. 12(2), 107–110 (2001).
  • Oskay UY, Beji NK, Yalcin O. A study on urogenital complaints of postmenopausal women aged 50 and over. Acta Obstet. Gynecol. Scand. 84(1), 72–78 (2005).
  • Chen YC, Chen GD, Hu SW, Lin TL, Lin LY. Is the occurrence of storage and voiding dysfunction affected by menopausal transition or associated with the normal aging process? Menopause 10(3), 203–208 (2003).
  • The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 14(3), 357–369 (2007).
  • The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17(2), 242–255 (2010).
  • The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 19(3) 257–271 (2012).
  • Davila GW, Singh A, Karapanagiotou I et al. Are women with urogenital atrophy symptomatic? Am. J. Obstet. Gynecol. 188, 382–388 (2003).
  • Suckling JA, Kennedy R, Lethaby A, Roberts H. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 4, CD001500 (2006).
  • Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 12(2), 91–105 (2009).
  • Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet. Gynecol. 92(4 Pt 2), 722–727 (1998).
  • Crandall C. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. J. Womens Health (Larchmt) 11(10), 857–877 (2002).
  • Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 17(1), 194–203 (2010).
  • Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet. Gynecol. 112(5), 1053–1060 (2008).
  • Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet. Gynecol. 111(1), 67–76 (2008).
  • Kao A, Binik YM, Kapuscinski A, Khalife S. Dyspareunia in postmenopausal women: a critical review. Pain Res. Manag. 13(3), 243–254 (2008).
  • Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N. Engl. J. Med. 357(8), 762–774 (2007).
  • Gast MJ, Freedman MA, Vieweg AJ, De Melo NR, Girão MJ, Zinaman MJ; Dyspareunia Study Group. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 16(2), 247–256 (2009).
  • Kingsberg SA. The sexual health benefits of oral low-dose estrogen plus progestogen and vaginal estrogen for postmenopausal women. Menopause 16(2), 224–225 (2009).
  • Labrie F, Cusan L, Gomez JL et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 16(1), 30–36 (2009).
  • Dorr MB, Nelson AL, Mayer PR et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil. Steril. 94(6), 2365–2368 (2010).
  • Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CMA. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst. Rev. 4, CD001405 (2009).
  • Enzelsberger H, Schatten C, Kurz C, Zorzi P. [Treatment of female incontinence by local oestrogen therapy.] Gynaekologische Rundschau 30(Suppl. 1), 235–236 (1990).
  • Enzelsberger H, Kurz C, Schatten C, Huber J. [The effectiveness of intravaginal estriol tablet administration in women with incontinence.] Geburtshilfe Frauenheilkd. 51(10), 834–838 (1991).
  • Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic Baldani D, Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int. J. Gynaecol. Obstet. 82(2), 187–197 (2003).
  • Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 329(11), 753–756 (1993).
  • Cardozo L, Lose G, McClish D, Versi E, de Koning Gans H. A systematic review of estrogens for recurrent urinary tract infections: third report of the Hormones and Urogenital Therapy (HUT) Committee. Int. Urogynecol. J. Pelvic Floor Dysfunct. 12(1), 15–20 (2001).
  • Pinggera GM, Feuchtner G, Frauscher F et al. Effects of local estrogen therapy on recurrent urinary tract infections in young females under oral contraceptives. Eur. Urol. 47(2), 243–249 (2005).
  • Bateson DJ, Weisberg E. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears. Menopause 16(4), 765–769 (2009).
  • Felding C, Mikkelsen AL, Clausen HV, Loft A, Larsen LG. Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas 15(3), 241–249 (1992).
  • Weiderpass E, Baron JA, Adami HO et al. Low-potency oestrogen and risk of endometrial cancer: a case–control study. Lancet 353(9167), 1824–1828 (1999).
  • Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 14(1), 23–31 (1991).
  • Weisberg E, Ayton R, Darling G et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 8(1), 83–92 (2005).
  • Dugal R, Hesla K, Sørdal T, Aase KH, Lilleeidet O, Wickstrøm E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet. Gynecol. Scand. 79(4), 293–297 (2000).
  • Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M; VAG-1748 Trial Investigators. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric 13(3), 228–237 (2010).
  • Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet. Gynecol. 116(4), 876–883 (2010).
  • Bachmann G, Bouchard C, Hoppe D et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 16(4), 719–727 (2009).
  • Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 13(2), 99–107 (1991).
  • Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7(3), 156–161 (2000).
  • Casper F, Petri E and the Vaginal Ring Study Group. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Int. Urogynecol. J. 10, 171–176 (1999).
  • Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Am. J. Obstet. Gynecol. 201(1), 5–11 (2009).
  • Salminen HS, Sääf ME, Johansson SE, Ringertz H, Strender LE. The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial. Maturitas 57(4), 370–381 (2007).
  • Santen RJ, Demers L, Ohorodnik S et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72(8), 666–671 (2007).
  • Bachmann G. The estradiol vaginal ring – a study of existing clinical data. Maturitas 22(Suppl. 22), S21–S29 (1995).
  • Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17β-estradiol vaginal tablets. Climacteric 13(3), 219–227 (2010).
  • Haspels AA, Luisi M, Kicovic PM. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas 3(3–4), 321–327 (1981).
  • Lokkegaard E, Nielsen A, Nielsen L, Lidegaard O. Risk of stroke with postmenopausal hormone therapy: A National Cohort Study. Presented at: The 38th Nordic Congress of Obstetrics and Gynecology. Bergen, Norway, 17–19 June 2012.
  • Cicinelli E, Di Naro E, De Ziegler D et al. Placement of the vaginal 17β-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17β-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety. Am. J. Obstet. Gynecol. 189(1), 55–58 (2003).
  • Biglia N, Peano E, Sgandurra P et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol. Endocrinol. 26(6), 404–412 (2010).
  • Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr. Relat. Cancer 6(2), 187–195 (1999).
  • Eden JA, Bush T, Nand S, Wren BG. A case–control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 2(Suppl. 2), 67–72 (1995).
  • Lars HL, Ole-Erik IO, Carl MR et al.; The HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst. 100, 475–482 (2008).
  • von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J. Natl Cancer Inst. 97(7), 533–535 (2005).
  • Alatas E, Yagci B, Oztekin O, Sabir N. Effect of hormone replacement therapy on clitoral artery blood flow in healthy postmenopausal women. J. Sex. Med. 5(10), 2367–2373 (2008).
  • Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal Phase 3 study. Menopause 17(3), 480–486 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.